Beam Therapeutics' BEAM-302 Shows Compelling Phase 1/2 Data, Advances to Pivotal AATD Trial
BEAM sits 95% above its 52-week low of $13.525.
Summary
Beam Therapeutics announced compelling updated Phase 1/2 clinical data for its gene-editing candidate, BEAM-302, in Alpha-1 Antitrypsin Deficiency (AATD). The data demonstrated significant efficacy, with patients achieving a mean steady-state total AAT level of 16.1 µM and an 84% reduction in mutant Z-AAT, along with a well-tolerated safety profile. This positive outcome has led the company to select 60 mg as the optimal dose and confirms plans to initiate a global pivotal cohort in the second half of 2026. Advancing a lead gene-editing candidate with strong efficacy and safety into pivotal development is a major de-risking event for Beam Therapeutics, significantly enhancing its pipeline value and potential for future commercialization. Traders will now monitor the initiation of the pivotal trial and subsequent regulatory progress.
At the time of this announcement, BEAM was trading at $26.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $13.53 to $36.44. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.